Oncotalks | Powered by Novartis

Section 5: Q&A (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)

Switzerland , Hungary
Share this item

Section 5: Q&A (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)

Related items

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania

00:03:29

ESMO 2019 Highlights on melanoma presented at ESMO 2019

ESMO 2019 Highlights on melanoma presented at ESMO 2019

Philippe Saiag, MD, PhD and Prof. Jean Jacques Grob, MD are sharing their personal hightlights on melanoma from ESMO 2019

ESMO , Latvia , Lithuania , Estonia , Hungary , Albania

00:02:10

ASCO 2019 Prof. Dirk Schadendorf, MD

ASCO 2019 Prof. Dirk Schadendorf, MD

Prof. Dirk Schadendorf, MD from the University Hospital Essen, Germany is commenting on his abstract that was presented at ASCO 2019 in ChicagoSchadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582)

ASCO , Latvia , Lithuania , Estonia , Hungary , Albania

00:10:57

SABCS 2019 - Patrick Neven; PD2-08 Gene expression analysis and association with treatment response in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer in the MONALEESA-3 study

SABCS 2019 - Patrick Neven; PD2-08 Gene expression analysis and association with treatment response in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer in the MONALEESA-3 study

Patrick Neven is commenting on the poster: PD2-08 Gene expression analysis and association with treatment response in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer in the MONALEESA-3 study

SABC , Kisqali Channel , Hungary , Lithuania , Albania

00:02:25

SABCS 2019 - Elisabetta Munzone; Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2- advanced breast cancer

SABCS 2019 - Elisabetta Munzone; Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2- advanced breast cancer

Elisabetta Munzone is commenting on the poster: P1-19-06 Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2- advanced breast cancer

SABC , Hungary , Lithuania , Albania , Slovenia

00:04:06

ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Conleth Murphy, MD, PhD from the Bon Secours Cork Cancer Centre, Cork, Ireland is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

ESMO , Kisqali Channel , Hungary , Lithuania , Albania

00:03:01